N/A N=41 A Study of Rituximab in Combination With Chemotherapy in Relapsed/Refractory Follicular Lymphoma
Lymphoma, Follicular
Primary: Percentage of Participants With Objective Response — 92.3 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=503 Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Phase 3 N=358 Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Lymphoma, Non-Hodgkin
Primary: Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria…
Phase 2 N=28 Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL
Lymphoma
Primary: Progression-free Survival at 1 Year — 38 percentage of participants
Phase 2 N=24 Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Refractory Follicular Lymphoma · Relapsed Follicular Lymphoma
Primary: Recommended Phase 2 Dose (RP2D) — 0; 1; 0; 0 Dose Limiting toxicities
Phase 2 N=97 Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Lymphoma
Primary: Overall Response Rate — 53.3; 76.1 percentage of participants — p=0.29
Phase 2 N=98 Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma
Follicular Lymphoma
Primary: Complete Response Rate (CRR) Per Independent Review Committee (IRC) Assessment — 69.1 Percentage of participants
Phase 2 N=64 Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma
Follicular Lymphoma
Primary: Progression-free Survival — 59 percent chance of PFS at 5 years
Phase 2 N=16 Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma
Follicular Lymphoma
Primary: Number of Participants With Overall Response Rate (ORR) — 0; 0; 0; 0 participants
Phase 2 N=49 Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
Lymphoma
Primary: Number of Participants With Time to Progression (TTP) — 42; 4 Participants
Phase 2 N=60 R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial
Non-Hodgkin's Lymphoma
Primary: Response Rate — 57; 35 Participants
Phase 2 N=64 Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT
Diffuse Large B-Cell Lymphoma
Primary: Overall Response (OR) Rate — 36 Participants
Phase 2 N=116 HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab
Lymphoma, Follicular
Primary: Number of Participants With Objective Response (OR) — 0; 1; 2; 0 participants
Phase 2 N=25 Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: Response Rate = Complete and Partial Response at 12 Weeks. — 5; 3; 2; 15 participants
Phase 2 N=30 Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Follicular Lymphoma · Marginal Zone Lymphoma · Mantle Cell Lymphoma
Primary: All Phase I-II Participants: Overall Response Rate (ORR) — 28 percentage of participants
Phase 2 N=65 Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma · Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma · Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma
Primary: Number of Participants Who Achieved a Complete Response — 47 Participants
Phase 2 N=92 Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)
Lymphoma
Primary: Overall Response Rate (ORR) as Determined by IRRC — 4.3 Percentage of participants
N/A N=260 Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE)
Follicular Lymphoma
Primary: Percentage of Participants With Modalities of the Therapeutic Decision Before First Study Induction Treatment Phase — 81.9; 8.4; 6.3; 3.4 percentage of participants
Phase 2 N=126 A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma
Lymphoma
Primary: Objective Response Rate With Parsaclisib Based on Lugano Classification Response Criteria — 65.2; 77.7 percentage of participants
Phase 2 N=131 A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Non-Hodgkin's Lymphoma
Primary: Percentage of Participants With CR at EOI Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography (PET) and Computed Tomography…
Phase 2 N=38 A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Lymphoma, Follicular
Primary: Percentage of Participants Achieving Complete Response (CR) at End of Induction (EOI), as Determined by the Independent Review Committee (IRC) Using Modified Lugano 2014…
Phase 2 N=21 TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
Grade 1 Follicular Lymphoma · Grade 2 Follicular Lymphoma · Grade 3a Follicular Lymphoma
Primary: Number of Dose-limiting Toxicity Assessed Using Common Terminology Criteria for Adverse Events Version 4.0 (Phase Ib) — 1; 0 Participants
Phase 2 N=9 Phase 2 Study of Bexxar in Relapsed/Refractory DLCL
Lymphoma
Primary: Clinical Response Rate — 2; 0; 1; 1 participants
Phase 2 N=38 Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
Adult Non-Hodgkin Lymphoma · Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Nodal Marginal Zone Lymphoma
Primary: Maximum Tolerated Dose of CpG 7909 as Determined Using the Number of Participants With a DLT at Each Dose Level — 0; 1; 0; 1 participants
Phase 2 N=71 CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Recurrent Mantle Cell Lymphoma
Primary: Overall Response Rate (Complete and Partial Responses) as Defined by the International Workshop Criteria — 62.5; 52.4 percentage of patients
Phase 2 N=55 Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma
Relapsed Follicular Lymphoma
Primary: Number of Patients With Complete Response (CR) — 1; 13 participants
Phase 2 N=13 Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: Number of Participants With Response (Complete Response or Progressive Disease) — 2; 6 Participants
Phase 2 N=50 Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)
Non-Hodgkins Lymphoma
Primary: Percentage of Participants With Response — 34.7 percentage of participants
N/A N=99 Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1
Follicular Lymphoma
Primary: Number of Participants With an Adverse Event (AE), Serious AE, or Death Related to AE — 34; 10; 7 participants
Phase 2 N=14 Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma · Hepatosplenic T-cell Lymphoma
Primary: Overall Response (OR) Rate — 0.07 Proportion of participants